GleamWall
中文EN

BIOM BIOMOLECULAR LIFE HOLDINGS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1091326 · Fiscal year ends 12/31

Financial factors as of 2015-09-30 (2015Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY51.4%
TTM EPS YoY91.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-381.4%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets431.7%
Debt / equity—
Current ratio0.01x
Interest coverage-1.32x

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-305.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2015Q32015-09-302015Q22015-06-302015Q12015-03-312014Q4*2014-12-312014Q32014-09-302014Q22014-06-302014Q12014-03-312013Q4*2013-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$140,151$162,790$159,648-$110,162$339,881$224,377$411,606$458,881
SG&A expense$118,712$127,060$138,469$180,853$64,637$296,245$369,620$1.27M
Operating income-$644,446-$739,266-$801,480-$541,450-$798,772-$1.15M-$1.65M-$2.13M
Interest expense$250,200$431,763$714,749$666,246$687,800$554,092$851,813$573,030
Net income-$1.01M-$1.40M-$1.46M-$424,500-$1.06M-$2.00M-$2.70M-$3.08M
EBITDA———-$541,450-$798,772——-$2.13M
EPS (basic)-0.01-0.02-0.03—-0.04-0.09-0.14—
EPS (diluted)-0.01-0.02-0.03—-0.04-0.09-0.14—
Weighted avg. shares (diluted)85.45M66.90M51.64M—28.94M22.78M18.88M—
Balance sheet
Cash & equivalents$22,919$4,335$30,066$33,992$53,842$32,852$148,666$713,892
Current assets$40,326$39,413$92,081$246,266$60,463——$789,386
PP&E, net$0$0$0$0$0——$0
Intangibles$1.08M$1.08M$1.08M$1.08M$1.08M——$1.08M
Total assets$1.12M$1.12M$1.17M$1.32M$1.14M——$1.87M
Current liabilities$5.46M$5.96M$5.89M$5.83M$6.31M——$6.33M
Total liabilities$4.82M$5.31M$5.24M$5.16M$5.63M——$5.64M
Shareholders' equity-$4.34M-$4.84M-$4.73M-$4.51M-$5.17M——-$4.47M
Shares outstanding101.50M77.31M61.45M46.22M31.23M——17.46M
Cash flow statement
Operating cash flow-$48,321-$237,561-$165,042-$407,412-$468,342-$308,934-$724,771-$539,803
Capital expenditure———$0———$0
Free cash flow———-$407,412———-$539,803
Investing cash flow———$0———$0
Financing cash flow$66,905$211,830$161,116$387,562$489,332$193,120$159,545$1.24M
Depreciation & amortization———$0$0——$0
Stock-based compensation$62,752$85,507$91,548$0-$590,480——$0

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.